Sort   by:  
 Page size 
UnknownSWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Not available
S-EPMC4417730 | biostudies-literature
TranscriptomicsThe Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment
Advancing age is associated with substantial increases in the incidence rates of common diseases affecting the prostate including benign prostatic hyperplasia (BPH) and prostate carcinoma. However, to date, there is no established molecular explanation for the age-dependent increases in these pathol...
ORGANISM(S): Mus musculus 
2010-09-15 | E-GEOD-21542 | biostudies-arrayexpress
TranscriptomicsAR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.
Androgen deprivation therapy remains the primary treatment modality for patients with metastatic prostate cancer but is uniformly marked by progression to castration-resistant prostate cancer (CRPC) after a period of regression. Continued activation of androgen receptor (AR) signaling is attributed ...
ORGANISM(S): Mus musculus 
2014-09-11 | E-GEOD-61303 | biostudies-arrayexpress
ProteomicsUnraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform to emergent aggressive variant prostate cancer (AVPC) which has neuroendocrine (NE)-like features. To this end, we used LuCaP patient-deriv...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-06-09 | MSV000092139 | MassIVE
ProteomicsUnraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform to emergent aggressive variant prostate cancer (AVPC) which has neuroendocrine (NE)-like features. To this end, we used LuCaP patient-deriv...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-06-09 | MSV000092137 | MassIVE
GenomicAnalysis of AR Gene Rearrangements in Prostate Cancer

Molecularly-targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signaling undermines therapeutic efficacy and promotes progression to lethal castration-resistant...

phs001223 | dbGaP
Sort   by:  
 Page size